ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,213.49
0.51%
Dow Jones
38,852.27
0.46%
Gold vs US Dollar
2,323.965
1.31%
Brent Oil
83.475
0.42%
Bitcoin
63,154.38
-1.32%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Citius Pharmaceuticals Inc (CTXR) Share Price

CTXR Citius Pharmaceuticals Inc

0.705
0.00 (0.00%)
After Hours
Last Updated: 00:24:06
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Citius Pharmaceuticals Inc NASDAQ:CTXR NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   0.00 0.00 0.705 0.6879 0.705 0.7359 0.67 0.7129 1,435,278 23:24:06   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Pharmaceutical Preparations  -33.69M -0.2118 -3.31 111.37M
 Type  Size  Price  Time  Units 
 20 600 0.705 23:08:21 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore CTXR News
30/04/202421:05PRNUSCitius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering
26/04/202413:00PRNUSCitius Pharmaceuticals Announces $15 Million Registered Direct Offering
11/04/202413:30PRNUSCitius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
04/04/202413:30PRNUSCitius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference
18/03/202412:30PRNUSCitius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
07/03/202413:30PRNUSCitius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program
04/03/202405:15EDGAR2Form EFFECT - Notice of Effectiveness
Period
Draw mode
Data Downloads for CTXR

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Citius Pharmaceuticals Inc Articles